Skip to content
Screener

Dianthus Therapeutics DNTH Q4 2025 Annual earnings

Reported March 9, 2026 · Before market open

Revenue$284.0KMiss by $268.2K
EPS-$1.43Miss by $0.45
Revenue estimate$552.2K
EPS estimate-$0.98

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$443.9K
EPS estimate-$0.94

Financials

Q4 2025

Balance sheet

See full
Cash & equivalents$51.1M+124%
Total debt$1.4M-7.0%
Total equity$493.4M+40.0%
Total assets$530.9M+42.0%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.77B+174%
Enterprise value$1.72B+175%

Returns & leverage

See full
Debt / equity0×0.0×
Current ratio13.3×-1.9×

FAQ

When did Dianthus Therapeutics report Q4 2025 earnings?
Dianthus Therapeutics (DNTH) reported Q4 2025 earnings on March 9, 2026 before market open.
What were Dianthus Therapeutics's Q4 2025 revenue and EPS?
Dianthus Therapeutics reported revenue of $284.0K and eps of $-1.43 for Q4 2025.
Did Dianthus Therapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $552.2K by $268.2K. EPS missed the consensus estimate of $-0.98 by $0.45.
How did Dianthus Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 78.6% from $1.3M a year earlier and eps declined 76.5% from $-0.81.
Where can I find Dianthus Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-097555) and the 10-K periodic report (0001690585-26-000006) directly on SEC EDGAR. The filing index links above go to sec.gov.